Ultragenyx Pharmaceutical Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Ultragenyx Pharmaceutical Inc Unternehmen

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Ultragenyx Pharmaceutical Inc Informationen



BörsenkürzelRARE

Name des UnternehmensUltragenyx Pharmaceutical Inc

IPO-datumJan 31, 2014

CEOKakkis (Emil D)

Anzahl der mitarbeiter1294

WertpapierartOrdinary Share

GeschäftsjahresendeJan 31

Addresse60 Leveroni Ct

StadtNOVATO

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl94949

Telefon14154838800

Websitehttps://www.ultragenyx.com/

BörsenkürzelRARE

IPO-datumJan 31, 2014

CEOKakkis (Emil D)

Führungskräfte von Ultragenyx Pharmaceutical Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-31783.00%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+31589.00%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+19104.00%

Mr. Michael A. Narachi

Independent Director

27.34K

+5740.00%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+5740.00%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+5740.00%

Dr. Amrit Ray, M.D.

Independent Director

18.02K

+5740.00%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

1.52K

-3150.00%

Mr. Matthew K. (Matt) Fust

Independent Director

--

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.69M

-31783.00%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

107.20K

+31589.00%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

41.99K

+19104.00%

Mr. Michael A. Narachi

Independent Director

27.34K

+5740.00%

Mr. Daniel G. Welch

Independent Chairman of the Board

27.34K

+5740.00%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.59K

+5740.00%

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Crysvita royalty revenue

64.94M

40.60%

Crysvita

47.00M

29.39%

Dojolvi

24.27M

15.18%

Evkeeza

16.72M

10.45%

Mepsevii

7.00M

4.38%

Nach RegionUSD

Name

Umsatz

Anteil

North America

83.54M

52.23%

Latin America

43.36M

27.11%

Europe

27.88M

17.43%

Asia Pacific

5.15M

3.22%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Crysvita royalty revenue

64.94M

40.60%

Crysvita

47.00M

29.39%

Dojolvi

24.27M

15.18%

Evkeeza

16.72M

10.45%

Mepsevii

7.00M

4.38%

Aktionärsstatistik

Aktualisiert: Sat, Feb 7

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

10.62%

BlackRock Institutional Trust Company, N.A.

5.26%

Fidelity Management & Research Company LLC

4.07%

Sands Capital Management, LLC

3.91%

State Street Investment Management (US)

3.83%

Andere

72.32%

Aktionäre

Anteil

The Vanguard Group, Inc.

10.62%

BlackRock Institutional Trust Company, N.A.

5.26%

Fidelity Management & Research Company LLC

4.07%

Sands Capital Management, LLC

3.91%

State Street Investment Management (US)

3.83%

Andere

72.32%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

52.00%

Investment Advisor/Hedge Fund

31.58%

Hedge Fund

14.45%

Individual Investor

3.48%

Research Firm

2.31%

Sovereign Wealth Fund

1.02%

Private Equity

1.02%

Pension Fund

0.82%

Bank and Trust

0.43%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

663

100.97M

104.66%

-1.43M

2025Q3

640

97.34M

100.90%

-3.53M

2025Q2

635

97.48M

101.32%

-2.63M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

2023Q3

574

75.90M

106.07%

-3.60M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

10.11M

10.48%

-80.69K

-0.79%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

5.07M

5.26%

+54.55K

+1.09%

Sep 30, 2025

Fidelity Management & Research Company LLC

3.92M

4.07%

+1.65M

+72.84%

Sep 30, 2025

Sands Capital Management, LLC

3.77M

3.91%

-173.63K

-4.40%

Sep 30, 2025

State Street Investment Management (US)

3.69M

3.83%

+1.12M

+43.55%

Sep 30, 2025

RTW Investments L.P.

3.26M

3.38%

+1.55M

+90.83%

Sep 30, 2025

JP Morgan Asset Management

3.25M

3.37%

+644.31K

+24.74%

Sep 30, 2025

Fidelity Institutional Asset Management

3.36M

3.48%

+3.02M

+906.25%

Sep 30, 2025

Baker Bros. Advisors LP

2.77M

2.87%

--

Sep 30, 2025

Kakkis (Emil D)

2.69M

2.79%

-31.78K

-1.17%

Mar 07, 2025

Verbundene ETFs



Aktualisiert: Tue, Dec 2

Name

Anteil

Motley Fool Small-Cap Growth ETF

3.73%

Global X Genomics & Biotechnology ETF

3.19%

Franklin Genomic Advancements ETF

1.59%

Virtus LifeSci Biotech Products ETF

1.41%

State Street SPDR S&P Biotech ETF

1.32%

WisdomTree BioRevolution Fund

0.94%

Direxion Daily S&P Biotech Bull 3X Shares

0.81%

Touchstone Sands Capital US Select Growth ETF

0.8%

Goldman Sachs Future Health Care Equity ETF

0.6%

First Trust Multi-Manager Large Growth ETF

0.54%

Motley Fool Small-Cap Growth ETF

Anteil3.73%

Global X Genomics & Biotechnology ETF

Anteil3.19%

Franklin Genomic Advancements ETF

Anteil1.59%

Virtus LifeSci Biotech Products ETF

Anteil1.41%

State Street SPDR S&P Biotech ETF

Anteil1.32%

WisdomTree BioRevolution Fund

Anteil0.94%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.81%

Touchstone Sands Capital US Select Growth ETF

Anteil0.8%

Goldman Sachs Future Health Care Equity ETF

Anteil0.6%

First Trust Multi-Manager Large Growth ETF

Anteil0.54%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten